



What should we fight for?

Dr Grania Brigden
Renewing the Fight against TB
27th October, Barcelona



Tuberculosis – the issues

- Difficult diagnosis
- Arduous treatment
- TB in children
- The need for more new drugs and regimens, i.e TB drug R&D

Where are we now?

- Review of various indicators for diagnosis, treatment and accessibility of key medicines, drug procurement and funding, in 8 high burden countries.
- From the results recommendations made for countries, global TB organisations, donors and drug manufacturers
- Released Thursday 30th October 11am



OUT OF STEP

DEADLY IMPLEMENTATION GAPS IN THE TB RESPONSE

A survey of TB diagnostic and treatment practices
in eight countries

October 2014

www.medicins.org



5 Deadly Gaps

- Diagnostic Gaps
- Treatment Gaps
- Models of Care
- Access to Drugs
- Funding



Diagnostic Gaps.

- Better access to DST
- Better tests
 - Point-of-care: easy to perform in peripheral health centres
 - What other rapid DST do we want?
 - Non-sputum based tests
- Drastic improvement in diagnosis of currently neglected populations: HIV co-infected patients and children

Treatment Gaps.

- Growing diagnosis of MDR-TB not matched by growing access to MDR-TB treatment



Out dated models of Care

- Treatment not matching WHO guidance
- Over-reliance on hospitalization
- Need to move towards decentralisation and a patient centred approach
- Individualisation of treatment presents challenges for programmatic scale up.





Access to New and Repurposed Drugs.

- New Drugs not available outside CU programmes
- Difficult or expensive access to Group 5 drugs
- Registration issues from companies and countries.
- Lack of drugs on EML and Treatment guidelines.
- Lack of paediatric formulations of new and SLD drugs.

TB the future and Innovation.





3Ps: Push + Pull + Pool

A mix of incentives & the collective management of IP:

- **Push** funding to finance R&D activities upfront (i.e. through grants)
- **Pull** funding to incentivise R&D activities through the promise of financial rewards on the achievement of certain R&D objectives (i.e. through milestone prizes)
- **Pooling** of intellectual property (IP) to ensure open collaborative research and fair licensing for competitive production of the final products

For more information: MSF's R&D Symposium, "Changing the status quo in TB drug and regimen R&D," on Friday 31 October at 14:30.



Thanks!